Login / Signup

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients.

Si-Yang LiuHao SunJia-Ying ZhouGuang-Ling JieZhi XieYang ShaoXian ZhangJun-Yi YeChun-Xiang ChenXu-Chao ZhangQing ZhouJin-Ji YangYi-Long Wu
Published in: Biomarker research (2020)
In the largest sample used thus for, our study found that approximately 10% of Chinese NSCLC patients had KRAS mutations. Of these, nearly 30% harbored the KRAS G12C mutation subtype, which was most common in male smokers. The KRAS G12C mutation is a biomarker of poor prognosis in Chinese NSCLC patients, which could potentially be improved by G12C-specific inhibitors in the future.(296 words).
Keyphrases
  • end stage renal disease
  • poor prognosis
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • wild type
  • epidermal growth factor receptor
  • brain metastases